Positive Quality Intervention: Olaparib (Lynparza®) Clinical Management

Description: Olaparib is a poly ADP-ribose polymerase (PARP) enzyme inhibitor and is FDA approved as a targeted therapy for BRCA-mutated breast cancer, ovarian, pancreatic cancer, as well as prostate cancer. This PQI will highlight its place in therapy in these disease states, safety profiles, and clinical pearls regarding dose adjustment.

Background: Breast Cancer - About 5-10% of breast cancers can be associated with gene mutations inherited from a parent, most commonly mutations in the BRCA1 and BRCA2 genes.\(^\text{12}\)

<table>
<thead>
<tr>
<th>Lifetime Risk of Developing Breast Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mutation</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>BRCA1</td>
</tr>
<tr>
<td>BRCA2</td>
</tr>
</tbody>
</table>

Ovarian Cancer - Currently, ovarian cancer is primarily treated with surgery and systemic chemotherapy. About 25% of ovarian cancer cases are related to a BRCA mutation (15% germline and 7% somatic).\(^\text{14,15}\)

Pancreatic Cancer - Up to 7% of patients with pancreatic cancer have a gBRCA mutation.\(^\text{16,17}\)

Prostate Cancer - Olaparib approved in May 2020 for patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer in combination with gonadotropin-releasing hormone analog or prior bilateral orchiectomy (full indication list in supplemental information).\(^\text{7}\)

PQI Process:
- Verify the dosage form is correct
  - Olaparib was previously available as both a tablet and a capsule, and the two dosage forms had different bioavailability and therefore were not interchangeable on a milligram-per-milligram basis
    - Capsules were discontinued August 2018 and only the tablets are currently available
  - Olaparib is available as 100 mg and 150 mg tablets
- Verify the dose is correct
  - Typical starting dose for all FDA-approved indications: 300 mg orally twice daily
    - See Supplemental Information Section for current FDA-approved indications
  - The dose of olaparib must be adjusted to 200 mg twice daily for renal dysfunction when creatinine clearance is \(< 50 \text{ mL/minute}\). Olaparib has not been studied in patients with creatinine clearance \(< 30 \text{ mL/minute}\)
- Dose adjustments for adverse reactions
  - Consider holding treatment or dose reductions if patients experience adverse reactions

<table>
<thead>
<tr>
<th>Dose reduction</th>
<th>Recommended Dose</th>
<th>How to Supply</th>
</tr>
</thead>
<tbody>
<tr>
<td>1(^\text{st}) dose reduction</td>
<td>250 mg BID</td>
<td>One 150 mg tablet + one 100 mg tablet BID</td>
</tr>
<tr>
<td>2(^\text{nd}) dose reduction</td>
<td>200 mg BID</td>
<td>Two 100 mg tablets BID</td>
</tr>
</tbody>
</table>

Important notice: NCODA has developed this Positive Quality Intervention platform. This platform represents a brief summary of medication uses and therapy options derived from information provided by the drug manufacturer and other resources. This platform is intended as an educational aid and does not provide individual medical advice and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication discussed in the platform and is not intended as a substitute for the advice of a qualified healthcare professional. The materials contained in this platform are for informational purposes only and do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA, which assumes no liability for and does not ensure the accuracy of the information presented. NCODA does not make any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional.
PQI Process Continued:

- Drug interactions
  - Avoid concomitant use with moderate and/or strong CYP3A4 inhibitors
    - If a strong CYP3A4 inhibitor must be used concomittantly, the olaparib dose should be reduced to 100 mg twice daily
    - If a moderate CYP3A4 inhibitor must be used concomittantly, the olaparib dose should be reduced to 150 mg twice daily
  - Avoid concomitant strong CYP3A inducers; if a moderate CYP3A inducer must be used, there is the potential for reduced efficacy of olaparib
- Laboratory monitoring
  - Complete blood counts should be performed at baseline and monthly thereafter
  - Renal function should be verified at baseline and periodically thereafter
  - Taking other antiangiogenesis agents may cause a potentiation/prolongation of myelosuppression

Patient Centered Activities:

- Provide Oral Chemotherapy Education (OCE) sheet
- Counsel patient on side effect profile (see supplemental information)
- Instruct patient to avoid grapefruit, grapefruit juice, Seville oranges, and/or Seville orange juice

Copay Assistance:

- Commercially insured patients who qualify can enroll in a $0 copay card assistance program through AstraZeneca’s Access 360 program

References:


Important notice: NCODA has developed this Positive Quality Intervention platform. This platform represents a brief summary of medication uses and therapy options derived from information provided by the drug manufacturer and other resources. This platform is intended as an educational aid and does not provide individual medical advice and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warnings, interactions, adverse effects, or risks associated with the medication discussed in the platform and is not intended as a substitute for the advice of a qualified healthcare professional. The materials contained in this platform are for informational purposes only and do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA, which assumes no liability for and does not ensure the accuracy of the information presented. NCODA does not make any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional.
### Supplemental Information:

**Current FDA-approved indications:** (Starting dose is 300 mg twice daily for all indications)

<table>
<thead>
<tr>
<th>Indication</th>
<th>Efficacy</th>
<th>Safety</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ovarian cancer</strong></td>
<td>· mPFS results: olaparib 56 months vs placebo 13.8 months (p-value &lt; 0.0001)</td>
<td>· Most common AEs with olaparib: nausea, vomiting, fatigue, anemia, diarrhea</td>
</tr>
<tr>
<td>First-line maintenance treatment for deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer for patients who are in a complete or partial response to first-line platinum-based chemotherapy (SOLO-1 trial)</td>
<td>· 5-Year PFS: olaparib 48% vs placebo 21%</td>
<td>· Serious AEs occurred in 21% of olaparib patients vs 12% of placebo patients, most commonly anemia</td>
</tr>
<tr>
<td>In combination with bevacizumab for maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer for patients who are in a complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either:</td>
<td>· Reduced the risk of disease progression or death by 67% (equal to HR of 0.33) and improved progression-free survival to a median of 37.2 months vs 17.7 months with bevacizumab alone</td>
<td>· Adverse reactions (Grade 1-4) occurring in ≥10% of patients treated with olaparib/bevacizumab in PAOLA-1 compared with the placebo/bevacizumab arm were nausea (53%), fatigue (including asthenia) (53%), anemia (41%), lymphopenia (24%), vomiting (22%), and leukopenia (18%), diarrhea (18%), neutropenia (18%), urinary tract infection (15%), and headache (14%)</td>
</tr>
<tr>
<td>· Deleterious or suspected deleterious BRCA mutation and/or</td>
<td>· Higher Risk: mPFS olaparib 36.0 vs. 16.0 bevacizumab</td>
<td></td>
</tr>
<tr>
<td>· Genomic instability PAOLA-1 trial</td>
<td>· Lower Risk: mPFS olaparib Not Reached vs. 22.1 bevacizumab</td>
<td></td>
</tr>
<tr>
<td>Maintenance treatment for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer for patients who are in a complete or partial response to platinum-based chemotherapy – 2 randomized trails completed</td>
<td>SOLO-2:</td>
<td>SOLO-2:</td>
</tr>
<tr>
<td>Study 19</td>
<td>· PFS: olaparib 19.1 months vs placebo 5.5 months, p-value &lt; 0.0001</td>
<td>· Most common grade 1-2 AEs in both groups: nausea, fatigue, vomiting, abdominal pain, and diarrhea</td>
</tr>
<tr>
<td></td>
<td>· OS: olaparib 51.7 months vs placebo 38.8 months, p-value 0.0537</td>
<td>· Most common grade 3 or higher AE with olaparib: anemia</td>
</tr>
<tr>
<td>Study 19</td>
<td></td>
<td>Study 19:</td>
</tr>
<tr>
<td></td>
<td>· PFS: olaparib 8.4 months vs placebo 4.8 months, p-value &lt; 0.0001</td>
<td>· Most common AEs of all grads in olaparib arm included nausea (71%), fatigue (63%), vomiting (35%), diarrhea (28%), anemia (23%), constipation (22%), respiratory tract infection (22%), decreased appetite (21%), and headache (21%)</td>
</tr>
<tr>
<td></td>
<td>OS: olaparib 29.8 months vs placebo 27.8 months (p-value 0.73)</td>
<td></td>
</tr>
<tr>
<td>Deleterious or suspected deleterious gBRCAm advanced ovarian cancer after ≥ 3 prior lines of chemotherapy</td>
<td>Single arm trial PFS results:</td>
<td>Serious AEs reported in 30% of patients, most frequently anemia, abdominal pain</td>
</tr>
<tr>
<td></td>
<td>· ORR: 34%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>· Median DoR: 7.9 months</td>
<td></td>
</tr>
</tbody>
</table>

Deleterious or suspected deleterious gBRCAm advanced ovarian cancer after ≥ 3 prior lines of chemotherapy
**Breast Cancer**

Deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer after treatment with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting (OlympiAD trial)

- PFS: olaparib 7 months vs chemotherapy 4.2 months (p-value 0.0009)

- Rate of grade 3 or higher AEs was lower with olaparib (36.6%) vs chemotherapy (50.5%)

- AEs that occurred more frequently with olaparib: anemia, nausea, vomiting, fatigue, headache, and cough

**Pancreatic Cancer**

Maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen (POLO trial)

- PFS results: olaparib vs. placebo: median 7.4 months vs 3.8 months (p-value 0.0035)

- ORR: 23% in olaparib arm (12% in placebo arm)

- OS: olaparib 19.3 months vs placebo 17.1 months (p-value NS)

- Most common AE at grades 3-4 for olaparib: anemia (11%)

- All grades AE >30% for olaparib: Fatigue (60%), nausea (45%), abdominal pain (34%)

- All grade diarrhea occurred at a rate of 29%

**Prostate Cancer**

Treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone (PROfound trial)

- Reduced risk of disease progression or death by 66% (HR 0.34, p-value <0.0001)

- Radiographic PFS median of 7.4 months vs 3.6 months with enzalutamide or abiraterone in men with BRCA1/2 or ATM gene-mutated mCRPC

- OS: olaparib 19.1 months vs placebo 14.7 months (p-value 0.0175)

- Most common AE (Grade 1-4) occurring in ≥10% in the olaparib arm (N=256) were anemia (46%), fatigue including asthenia (41%), decreased appetite (30%), diarrhea (21%), vomiting (18%), thrombocytopenia (12%), cough (11%) and dyspnea (10%)

- Venous thromboembolic events, including pulmonary embolism occurred in 7% of patients with mCRPC who received olaparib plus androgen deprivation therapy (ADT) compared to 3.1% of patients receiving enzalutamide or abiraterone plus ADT

PFS: progression free survival; AEs: adverse events; ORR: objective response rates; DoR: duration of response

Based on current February 2020 ASCO Guidelines:

- Women diagnosed with epithelial ovarian cancer
  - Offer germline genetic testing for BRCA1/2 and other ovarian cancer susceptibility genes at time of diagnoses
  - Perform somatic tumor testing for BRCA1/2 and other likely pathogenic variants in women who are negative for a germline mutation
  - First/second-degree blood relatives with a known germline susceptible gene mutation/variant should be offered individualized genetic risk evaluation/counseling and genetic testing
  - Genetic evaluations can be conducted in conjunction with health care professionals including genetic counselors